The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
|Articles|February 5, 2008
Government releases new statistics on shingles
Washington - More than 1 million Americans contract shingles every year, and nearly 1 million are seeking treatment for the condition, according to recently released government statistics, Reuters reports.
Advertisement
Washington - More than 1 million Americans contract shingles every year, and nearly 1 million are seeking treatment for the condition, according to recently released government statistics, Reuters reports.
Basing its study on several national surveys, the Agency for Healthcare Research and Quality reports that 1.1 million become infected with shingles every year, while about 900,000 seek treatment for it.
The agency reports that the average cost for treating shingles is $525 per person, or $566 million annually.
Advertisement
Related to this article
The novel oral helicase-primase inhibitor demonstrated significantly higher rates of complete lesion healing compared with investigator’s choice treatment in the phase 3 PRIOH-1 trial.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
Topical vs Oral JAK Inhibitors for Vitiligo: How to Choose as Systemic Options Advance
4
Don't Be Rash: Balancing Topical Steroids in the Era of Nonsteroidals
5